Today: 21 March 2026
Subscribe
Browse Category

NASDAQ:BCRX 14 October 2025 - 2 March 2026

BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

BioCryst Pharmaceuticals shares fell 2.9% to $8.50 premarket Monday after new clinical data on its hereditary angioedema drug pipeline. Interim results from the ALPHA-SOLAR study showed navenibart reduced mean monthly HAE attacks by 91% among 29 patients, with one discontinuation due to cancer. The company reaffirmed 2026 revenue guidance for ORLADEYO and expects a Phase 3 navenibart filing by late 2027.
2 March 2026
·
Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

Astria Therapeutics shares surged up to 50% on Oct. 14, 2025, after BioCryst Pharmaceuticals agreed to acquire the company in a cash-and-stock deal valuing ATXS at about $13 per share. Halper Sadeh LLC announced an investigation into the fairness of the sale. Astria’s lead drug navenibart is in Phase 3 trials for hereditary angioedema, with topline data expected in early 2027.
14 October 2025
···

Stock Market Today

  • Micron and FedEx Shine with Blowout Earnings Amid Market Turmoil
    March 20, 2026, 10:15 PM EDT. Micron Technology and FedEx reported strong quarterly earnings that stand out in a week marked by broader market declines fueled by surging oil prices and economic uncertainty linked to the Iran conflict. Micron's fiscal Q2 revenue soared nearly threefold to $23.86 billion, driven by high demand for AI-related memory products, topping earnings per share (EPS) estimates by over 38%. The company projects robust Q3 sales growth at $33.5 billion and anticipates exceeding $100 billion in annual sales next year. FedEx posted a fiscal Q3 EPS of $5.25, beating estimates by nearly 27%, supported by disciplined operations and digital efficiencies. It raised full-year EPS guidance to $19.30-$20.10, surpassing Wall Street forecasts. Both stocks could appeal to investors seeking buy-the-dip opportunities amid volatile trading.
Go toTop